Board Member
Karyopharm Therapeutics Inc. (KPTI)Equibles does not estimate personal net worth.
Get an email with a short summary when Karyopharm Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get KPTI alertsRichard Paulson is recorded as CEO and Board Member at Karyopharm Therapeutics Inc. (KPTI). The newest filing on record that lists Richard Paulson as CEO and Board Member at Karyopharm Therapeutics Inc. (KPTI) is dated April 13, 2026. Karyopharm Therapeutics Inc. reported in an 8-K filed May 31, 2024 that Richard Paulson was appointed Class II director, effective May 29, 2024. The proxy statement of Karyopharm Therapeutics Inc. reports total compensation of $2,320,902 for Richard Paulson in fiscal 2025, including a base salary of $770,000. Disclosed compensation is on record for 5 fiscal years. Richard Paulson has spoken on 20 earnings calls and 2 other investor events across 1 company, most recently for Karyopharm Therapeutics Inc. on August 13, 2026. Karyopharm Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Karyopharm Therapeutics Inc. includes Senior Clinical (CEO), Michael Mano (General Counsel), Kristin Abate (Chief Accounting Officer) and 7 others.
“The Company's stockholders elected Deepika R. Pakianathan, Richard Paulson and Chen Schor as Class II directors, each to serve on the Board for a three-year term until the 2027 annual meeting of stockholders and until his or her resignation or removal or until his or her successor is duly elected and qualified.”
“The second quarter marked the beginning of an important new chapter for Teriopharm, as we advanced Selenexor from a compelling and differentiating Phase III data set toward our planned supplemental new drug application under the FDA's accelerated approval pathway for patients with myelofibrosis.”
“As usual, right, just a little house cleaning. Certain statements might be forward-looking statements, so please refer to our latest 8K on filing.”
“And maybe I'll let Reshma expand on that, but a little housekeeping. Obviously, certain statements we make may be forward-looking statements, so please refer to our most recent 10Q. Reshma.”
“Carrier Farm continues to execute through an important period for the company, with recent and upcoming milestones that we believe can unlock meaningful growth opportunities and shape our next phase.”
“Here in 2026, Karyopharm is in a defining phase, marked by important late-stage clinical milestones, continued disciplined execution, and the opportunity to meaningfully expand the impact and scale of our oncology franchise.”
Start not stated–present
Last confirmed April 13, 2026
Start not stated–present
Last confirmed April 13, 2026
Biotechnology · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Karyopharm Therapeutics Inc. (KPTI) | President and Chief Executive Officer | $770,000 | $2,320,902 |
| 2024 | Karyopharm Therapeutics Inc. (KPTI) | President and Chief Executive Officer | $769,600 | $2,069,341 |
| 2023 | Karyopharm Therapeutics Inc. (KPTI) | President and Chief Executive Officer | $740,000 | $2,626,288 |
| 2022 | Karyopharm Therapeutics Inc. (KPTI) | President and Chief Executive Officer | $696,800 | $6,910,015 |
| 2021 | Karyopharm Therapeutics Inc. (KPTI) | President and Chief Executive Officer | $468,365 | $8,355,172 |
